‘Memorandum of Understanding’
(MOU) signing between Medtronic and Yashoda Group of Hospitals at Yashoda
Superspeciality Hospital & Cancer Institutes, Ghaziabad
Ghaziabad, 15 November 2024:
Yashoda Group of Hospitals, a premier multi-speciality and super-speciality
hospital with 800+ beds in Ghaziabad, Delhi-NCR, has signed a Memorandum of
Understanding (MoU) with Medtronic, a global leader in healthcare technology to
expand its capabilities for robotic-assisted surgery. Through this
collaboration, the Yashoda Group designates Medtronic as its Preferred Robotics
Partner and will integrate Medtronic's advanced robotic systems across its
hospitals and also partner for surgical robotics training programs.
The surgical robot Hugo Robotic Assisted
Surgery (RAS), already installed in Yashoda Group’s Sanjay Nagar unit, is being
used to facilitate surgeons in performing complex surgeries with precision and
ease. With the expansion of the surgical robotics program, Yashoda Group is
poised to achieve a new milestone that will revolutionise the way surgeries are
performed.
Robotic surgery, with its advantages over
conventional open and laparoscopic surgeries such as faster recovery time,
lesser blood loss, reduced chances of infection, shorter hospitalisation, and
the ability to perform the most complicated surgeries, is fast becoming the
need of the hour.
“This is a historic moment for not just
Yashoda but also the whole country. With the expansion of our robotics surgery
system capability, we are determined to bring the benefits of minimally
invasive surgery to more patients and advance surgical robotics in India’’ said Dr.
Dinesh Arora, Chairman, Yashoda Group of Hospitals.
Medtronic's Hugo RAS is a cutting-edge robotic-assisted surgery solution featuring an open console, modular arms, and a universal system tower. Its best-in-class vision system allows surgeons to view minute anatomical details. The rotation multiplier aids in fast suturing, while the tilt feature and pistol grip controllers enhance motion range and ease of complex procedures, minimising complications. Hugo is integrated with Touch Surgery™️, which safely records and stores surgical data, accessible from anywhere, anytime.
The signing of the Memorandum of
Understanding (MoU) was a momentous occasion, graced by the presence of
distinguished dignitaries and key stakeholders from both the Yashoda Group of
Hospitals and Medtronic. The event took place at the Yashoda Superspeciality
Hospital & Cancer Institutes in Ghaziabad, underscoring the importance of
this strategic partnership.
Rajit Kamal, Global Vice President &
General Manager, Surgical Robotics, Medtronic, "With nearly 70% of surgeries in India
still performed as open procedures, our partnership with Yashoda Group is
crucial for transforming surgical care. By leveraging the RAS system, we aim to
revolutionise surgical practices and reduce barriers to minimally invasive
surgery. This collaboration underscores our global commitment to advancing
healthcare where innovation is needed most."
Mandeep Singh Kumar, Managing Director and
Vice President of Medtronic India, stated, "Medtronic is pleased to partner with
Yashoda Group to advance robotic-assisted surgery across India. This
collaboration combines our surgical expertise with the innovative
Robotic-assisted surgery (RAS) system, leveraging data analytics and AI to
redefine Medtech. We are committed to our mission of impacting lives by
providing advanced surgical care and improving patient outcomes."
"This partnership will not only benefit our doctors but also those from other healthcare institutions. With this collaboration, the Yashoda Group will be able to train aspiring doctors across the country who are eager to gain proficiency in robotic surgery," stated Dr. Rajat Arora, Group Director, Yashoda Group of Hospitals.
About Medtronic:
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading
global healthcare technology company that boldly attacks the most challenging
health problems facing humanity by searching out and finding solutions. Our
Mission — to alleviate pain, restore health, and extend life — unites a global
team of 95,000+ passionate people across more than 150 countries. Our
technologies and therapies treat 70 health conditions and include cardiac
devices, surgical robotics, insulin pumps, surgical tools, patient monitoring
systems, and more. Powered by our diverse knowledge, insatiable curiosity, and
desire to help all those who need it, we deliver innovative technologies that
transform the lives of two people every second, every hour, every day. Expect
more from us as we empower insight-driven care, experiences that put people
first, and better outcomes for our world. In everything we do, we are
engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and
follow Medtronic on LinkedIn.
Any forward-looking statements are subject to
risks and uncertainties such as those described in Medtronic's periodic reports
on file with the Securities and Exchange Commission. Actual results may differ
materially from anticipated results. No statements or comments made in this
release may be construed as medical advice and patients need to consult their
physicians for the same.